Understanding the Popularity of Ozempic for Weight Loss: How Many People Are Taking It?

Last reviewed: July 6, 2026

Last updated: July 6, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Nobody can tell you exactly how many people are taking Ozempic for weight loss, and the reason is structural: Ozempic has no weight-management indication, so that use is off-label and no dataset records the prescriber's intent. What can be measured — spending, prevalence surveys, and refill behavior — tells a clearer story than any headline number. Total U.S. spending on GLP-1 receptor agonists rose from $13.7 billion in 2018 to $71.7 billion in 2023, an increase of more than 500%, with Ozempic alone going from $0.4 billion to $26.4 billion. In 2024, 26.5% of U.S. adults with diagnosed diabetes reported using a GLP-1 injectable. And in a cohort of 125,474 adults with overweight or obesity, most had stopped their GLP-1 medication within a year of starting. Popularity, prevalence, and persistence are three different things.

Why "How Many People Take Ozempic for Weight Loss" Has No Clean Answer

The Ozempic prescribing information lists three indications, all anchored to type 2 diabetes: improving glycemic control, reducing the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, and reducing the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. There is no obesity indication and no BMI threshold in that label.

Pharmacy claims record what was dispensed, not why. A prescription for Ozempic written for a patient who has both type 2 diabetes and obesity looks identical in the data to one written purely for glycemic control. That is why credible analyses report on GLP-1 receptor agonists as a class, or on the specific products that carry weight-management indications — Wegovy for semaglutide, Zepbound for tirzepatide — rather than attempting to split Ozempic by intent.

What the Spending Data Shows

The clearest picture of scale comes from an economic evaluation published in JAMA Network Open in 2025 by researchers at the American Medical Association and the CDC, using Symphony Health data capturing 85% of retail and 74% of mail-order prescription fills among adults aged 18 and older, inflation-adjusted to 2023 dollars.

Total GLP-1 spending grew by a mean of 34% per year from 2018 to 2022, then jumped 62% between 2022 and 2023. Ozempic went from $0.41 billion to $26.42 billion over that period; Trulicity from $5.60 billion to $17.57 billion; combined liraglutide and exenatide spending fell from $7.1 billion to $3.1 billion. By 2023, semaglutide and tirzepatide products together accounted for 70% of all GLP-1 spending. The finding most people miss: in 2023, products with an approved indication of type 2 diabetes accounted for 89% of all spending, while products with an approved obesity indication accounted for 11%. The category's growth is still overwhelmingly concentrated in diabetes-labeled products.

What the Survey Data Shows

For actual person-level prevalence, the most authoritative recent U.S. figure comes from the National Center for Health Statistics. NCHS Data Brief No. 537, published August 2025 using 2024 National Health Interview Survey data, reports that 26.5% of adults with diagnosed diabetes used a GLP-1 injectable — defined as reporting use of an injectable medication other than insulin to lower blood sugar or lose weight.

The breakdowns are informative. Use rose with age from 25.3% among adults 18–34 to 33.3% among those 50–64, then fell to 20.8% among adults 65 and older — a pattern consistent with Medicare's historical treatment of weight-loss agents. Use was similar between men (25.9%) and women (27.2%). By body mass index, use ranged from 16.7% among adults at a healthy weight to 32.4% among adults with obesity. That last gradient is the closest publicly available proxy for weight-driven use within a diabetes population.

The Denominator Behind the Demand

The scale of interest is easier to understand alongside the scale of the underlying condition. Per NCHS estimates from the National Health and Nutrition Examination Survey covering August 2021 through August 2023, 40.3% of U.S. adults ages 20 and older had obesity. When four in ten adults meet the clinical definition and a class of medications produces double-digit percentage weight reduction in trials, the resulting demand is not a fad — it is a population-level condition meeting an effective intervention for the first time at this scale.

That framing matters because it explains the supply pressure, the compounding market that grew around it, and the coverage fights that followed. It also explains why a product approved for diabetes became a household name for something it is not approved to treat.

Popularity Is Not the Same as Persistence

A retrospective cohort study published in JAMA Network Open in 2025 followed 125,474 adults with overweight or obesity who newly started liraglutide, semaglutide, or tirzepatide between 2018 and 2023, using electronic health record data from a collective of U.S. health systems. Mean age was 54.4 years and 65.4% were women; 61.0% had type 2 diabetes.

One-year discontinuation was 64.8% among patients without type 2 diabetes and 46.5% among those with it. Among those who discontinued, one-year reinitiation was 36.3% without diabetes and 47.3% with. Greater weight loss was associated with lower discontinuation — a 1% reduction in weight from baseline corresponded to roughly a 3% lower hazard of stopping — while moderate or severe gastrointestinal adverse events raised the hazard of stopping. Higher income was associated with lower discontinuation among patients with type 2 diabetes. The authors concluded that inequities in access and adherence have the potential to exacerbate disparities in obesity.

What the Comparative Evidence Says

A systematic review and network meta-analysis published in The BMJ in 2026, comprising 262 randomised trials and 99,791 participants across 19 drugs, put the class in context. Compared with lifestyle modification alone at one year, moderate to high certainty evidence showed weight loss of −14.9% with tirzepatide, −10.9% with oral semaglutide, and −9.8% with subcutaneous semaglutide. Subcutaneous semaglutide was the only drug associated with reduced all-cause mortality (risk ratio 0.81) and myocardial infarction (0.72), estimates largely informed by cardiovascular outcome trials in high-risk populations.

The same analysis was blunt about trade-offs: larger benefits were generally accompanied by greater harms and higher discontinuation, and no drug meaningfully improved quality-of-life scores beyond established minimally important differences across 43 trials and 45,663 participants. That is the honest version of the popularity story — real, measurable efficacy, real tolerability costs, and a decision that belongs in a conversation with a prescriber rather than in a trend piece.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test ($298) to personalize your protocol from day one.

Frequently Asked Questions

How many people are taking Ozempic for weight loss?

There is no reliable count, because Ozempic has no weight-management indication and pharmacy claims do not record why a prescription was written. Measurable proxies exist: U.S. spending on Ozempic rose from $0.41 billion in 2018 to $26.42 billion in 2023, and in 2024 the National Health Interview Survey found 26.5% of adults with diagnosed diabetes reported using a GLP-1 injectable.

Is Ozempic approved for weight loss?

No. Its label lists three indications, all tied to type 2 diabetes: improving glycemic control, reducing major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, and reducing the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. The semaglutide product approved for weight reduction is Wegovy.

How fast has GLP-1 use actually grown?

An economic evaluation in JAMA Network Open using Symphony Health data found total U.S. spending on GLP-1 receptor agonists rose from $13.7 billion in 2018 to $71.7 billion in 2023, an increase of more than 500%. Spending grew a mean of 34% per year through 2022, then 62% between 2022 and 2023. By 2023, semaglutide and tirzepatide products made up 70% of all GLP-1 spending.

Do most people stay on these medications?

Often not. In a cohort of 125,474 adults with overweight or obesity starting a GLP-1 receptor agonist between 2018 and 2023, one-year discontinuation was 64.8% among those without type 2 diabetes and 46.5% among those with it. Reinitiation within a year was 36.3% and 47.3% respectively. Greater weight loss predicted staying on treatment; moderate or severe gastrointestinal events predicted stopping.

How much weight do these medications produce in trials?

A 2026 BMJ network meta-analysis of 262 trials and 99,791 participants reported, versus lifestyle modification alone at one year, mean differences of −14.9% with tirzepatide, −10.9% with oral semaglutide, and −9.8% with subcutaneous semaglutide. The same analysis found larger benefits were generally accompanied by greater harms and higher discontinuation, and that no drug meaningfully improved quality-of-life scores.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.